00:08 , Jan 23, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Leukemia; cancer Cell culture and mouse studies identified an MDM2 protein degrader that could help treat leukemia and other cancers. Chemical synthesis and testing of analogs of an MDM2 inhibitor tool compound linked to...
05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
19:27 , Dec 21, 2018 |  BC Week In Review  |  Clinical News

Revlimid combo improves PFS by 25.3 months in Phase III for indolent lymphoma

Celgene Corp. (NASDAQ:CELG) reported additional data from the Phase III AUGMENT trial to treat relapsed or refractory follicular and marginal zone lymphoma showing that Revlimid lenalidomide plus Rituxan rituximab significantly improved median progression-free survival (PFS)...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
22:59 , Nov 1, 2018 |  BC Extra  |  Tools & Techniques

Selective degradation could be on horizon for imids

A Science study published Thursday suggests selective degradation of hard-to-drug zinc finger transcription factors could be achieved by modifying thalidomide or its analogs, collectively called imids. The results put forth a recipe to predict which...
21:35 , Aug 3, 2018 |  BC Extra  |  Preclinical News

Mechanism identified behind thalidomide-induced birth defects

Researchers at Dana-Farber Cancer Institute uncovered the mechanistic pathway by which thalidomide and two related analogs cause severe fetal harm, answering a long-held question about the three teratogenic drugs now used as cancer therapies. The...
16:36 , Jul 27, 2018 |  BC Week In Review  |  Clinical News

Celgene planning regulatory submissions for Revlimid in indolent lymphoma on Phase III win

Celgene Corp. (NASDAQ:CELG) said Revlimid lenalidomide plus Rituxan rituximab met the primary endpoint of improving progression-free survival (PFS) vs. placebo plus Rituxan in the Phase III AUGMENT trial to treat relapsed or refractory follicular and...
18:20 , Jun 15, 2018 |  BC Week In Review  |  Clinical News

Celgene reports detailed data from missed Phase III of Revlimid combo for follicular lymphoma

Celgene Corp. (NASDAQ:CELG) reported detailed data from the Phase III RELEVANCE trial of Revlimid lenalidomide plus Rituxan rituximab to treat previously untreated follicular lymphoma. The data were presented at the American Society of Clinical Oncology...
18:24 , Apr 19, 2018 |  BC Extra  |  Preclinical News

Increased ubiquitination of EZH2 or ALK for cancer therapies

Papers published in Cell Reports and Journal of Medicinal Chemistry suggest that targeted degradation by increasing ubiquitination of proteins that promote cancer could be a more complete strategy to treat cancer than catalytic inhibition. As...
16:04 , Mar 26, 2018 |  BC Extra  |  Preclinical News

Bradner, Gray explore targeted degradation-based model systems

C4 Therapeutics Inc. co-founders James Bradner and Nathanael Gray published a paper in Nature Chemical Biology demonstrating a generalizable target-specific protein degradation system that can be used to create preclinical models that offer better control...